Primary effusion lymphoma

Common Name(s)

Primary effusion lymphoma

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Primary effusion lymphoma" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Primary effusion lymphoma" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Primary effusion lymphoma" returned 143 free, full-text research articles on human participants. First 3 results:

Molecular mechanisms of activating c-MET in KSHV+ primary effusion lymphoma.
 

Author(s): Bao Quoc Lam, Lu Dai, Li Li, Jing Qiao, Zhen Lin, Zhiqiang Qin

Journal: Oncotarget. 2017 Mar;8(11):18373-18380.

 

The oncogenic Kaposi's sarcoma-associated herpesvirus (KSHV) is a principal causative agent of primary effusion lymphoma (PEL), which is mostly seen in immunosuppressed patients. PEL is a rapidly progressing malignancy with a median survival time of approximately 6 months even under ...

Last Updated: 14 Apr 2017

Go To URL
Up-regulation of tumor suppressor genes by exogenous dhC16-Cer contributes to its anti-cancer activity in primary effusion lymphoma.
 

Author(s): Yueyu Cao, Jing Qiao, Zhen Lin, Jovanny Zabaleta, Lu Dai, Zhiqiang Qin

Journal: Oncotarget. 2017 Feb;8(9):15220-15229.

 

Primary effusion lymphoma (PEL) is a rare and highly aggressive B-cell malignancy with Kaposi's sarcoma-associated herpesvirus (KSHV) infection, while lack of effective therapies. Our recent data indicated that targeting the sphingolipid metabolism by either sphingosine kinase inhibitor ...

Last Updated: 1 Feb 2017

Go To URL
Azidothymidine Sensitizes Primary Effusion Lymphoma Cells to Kaposi Sarcoma-Associated Herpesvirus-Specific CD4+ T Cell Control and Inhibits vIRF3 Function.
 

Author(s): Samantha J Williamson, Samantha M Nicol, Michael Stürzl, Shereen Sabbah, Andrew D Hislop

Journal:

 

Kaposi sarcoma-associated herpesvirus (KSHV) is linked with the development of Kaposi sarcoma and the B lymphocyte disorders primary effusion lymphoma (PEL) and multi-centric Castleman disease. T cell immunity limits KSHV infection and disease, however the virus employs multiple mechanisms ...

Last Updated: 28 Nov 2016

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Primary effusion lymphoma" returned 10 free, full-text review articles on human participants. First 3 results:

Human Herpesvirus Type 8-associated Large B-cell Lymphoma: A Nonserous Extracavitary Variant of Primary Effusion Lymphoma in an HIV-infected Man: A Case Report and Review of the Literature.
 

Author(s): William R Foster, Alina Bischin, Russell Dorer, David M Aboulafia

Journal: Clin Lymphoma Myeloma Leuk. 2016 06;16(6):311-21.

 

Primary effusion lymphoma (PEL) is a rare non-Hodgkin lymphoma subtype primarily seen in human immunodeficiency virus (HIV)-infected individuals with low CD4(+) cell counts and elevated HIV viral loads. It has always been associated with human herpesvirus type 8 (HHV-8) and in 80% ...

Last Updated: 17 Jun 2016

Go To URL
Human herpesvirus 8-unrelated primary effusion lymphoma-like lymphoma: report of a rare case and review of 54 cases in the literature.
 

Author(s): William Wu, Wonita Youm, Sherif A Rezk, Xiaohui Zhao

Journal: Am. J. Clin. Pathol.. 2013 Aug;140(2):258-73.

 

To report a patient with primary effusion lymphoma who was negative for human herpesvirus-8 (HHV-8), human immunodeficiency virus, Epstein-Barr virus, hepatitis C virus, and hepatitis B virus, as well as review 54 reported cases of HHV-8-unrelated primary effusion lymphoma (PEL)-like ...

Last Updated: 30 Jul 2013

Go To URL
Use of cidofovir for the treatment of HIV-negative human herpes virus-8-associated primary effusion lymphoma.
 

Author(s): Tamara K Moyo, Kristy L Richards, Blossom Damania

Journal: Clin Adv Hematol Oncol. 2010 May;8(5):372-4.

 

Last Updated: 16 Jun 2010

Go To URL
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Last Updated: 26 May 2017

Go to URL

Last Updated: 18 Oct 2017

Go to URL
Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas
 

Status: Not yet recruiting

Condition Summary: AIDS-Related Lymphoma; CD20 Positive; HIV Positivity; Stage II Diffuse Large B-Cell Lymphoma; Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma

 

Last Updated: 4 Sep 2017

Go to URL